Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma

Zhao, Yu; Wang, Shu; Qu, Yimin; Ji, Yuting; Shen, Keng; Lang, Jing He

doi:10.1186/s13048-017-0361-0

Cited by 9 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major factors that affect the prognosis in univariate analysis were reported as the following: menopausal status, FIGO staging, histological grade, lymph node dissection, ascites cytology, and hormone receptor expression. The main factors that significantly affect prognosis in multivariate analysis are grade 3 and lymph node dissection ( 111 , 145 ). Among them, FIGO staging is the most significant factor.…”

Section: Prognosis and Independent Prognostic Factorsmentioning

confidence: 99%

A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer

Chen

Qian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Ovarian cancer is one of the most common gynecologic cancers that has the highest mortality rate. Endometrioid ovarian cancer, a distinct subtype of epithelial ovarian cancer, is associated with endometriosis and Lynch syndrome, and is often accompanied by synchronous endometrial carcinoma. In recent years, dysbiosis of the microbiota within the female reproductive tract has been suggested to be involved in the pathogenesis of endometrial cancer and ovarian cancer, with some specific pathogens exhibiting oncogenic having been found to contribute to cancer development. It has been shown that dysregulation of the microenvironment and accumulation of mutations are stimulatory factors in the progression of endometrioid ovarian carcinoma. This would be a potential therapeutic target in the future. Simultaneously, multiple studies have demonstrated the role of four molecular subtypes of endometrioid ovarian cancer, which are of particular importance in the prediction of prognosis. This literature review aims to compile the potential mechanisms of endometrioid ovarian cancer, molecular characteristics, and molecular pathological types that could potentially play a role in the prediction of prognosis, and the novel therapeutic strategies, providing some guidance for the stratified management of ovarian cancer.

show abstract

Section: Prognosis and Independent Prognostic Factorsmentioning

confidence: 99%

A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer

Chen

Qian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Patients with stage IA/IB ovarian EC have a 5‐year survival of more than 95%, and the current consensus is that these patients can be spared adjuvant systemic therapy unless an undifferentiated component is diagnosed. However, the management for some stage IC patients has been called into question because their survival also seems to approach the 95% threshold . Thus, it is of importance to develop simple and reliable risk stratification methods to identify high‐risk patients who will benefit from systematic therapy, while sparing low‐risk patients the toxic side effect of multi‐agent chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…However, the management for some stage IC patients has been called into question because their survival also seems to approach the 95% threshold. [2][3][4][5] Thus, it is of importance to develop simple and reliable risk stratification methods to identify high-risk patients who will benefit from systematic therapy, while sparing lowrisk patients the toxic side effect of multi-agent chemotherapy. Multiple studies have aimed to identify prognostic biomarkers to help oncologists to stratify patient populations.…”

Section: Introductionmentioning

confidence: 99%

Nuclear β‐catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome

et al. 2019

View full text Add to dashboard Cite

Aims Ovarian endometrioid carcinoma (EC) generally has a good prognosis. Adjuvant chemotherapy can be spared in low‐stage disease, but prognostic biomarkers are needed to refine the treatment threshold. Wnt/β‐catenin signalling is commonly altered in EC. We examined immunohistochemical expression of nuclear β‐catenin and CDX2 as prognostic biomarkers for EC; both are mediators of the Wnt pathway. Methods and results We evaluated two ovarian EC cohorts, discovery set (n = 183) and validation set (n = 174), with ovarian cancer‐specific survival (OCSS) as the primary end‐point. In univariable analysis, nuclear β‐catenin expression was significantly associated with longer OCSS in the discovery set [hazard ratio (HR) = 0.36, 95% confidence interval (CI) = 0.16–0.74, P = 0.004] and the validation set (HR = 0.35, 95% CI = 0.11–0.89, P = 0.006). Similar significant associations were observed with CDX2 expression in the discovery set (HR = 0.25, 95% CI = 0.11–0.50, P < 0.001) and validation set (HR = 0.27, 95% CI = 0.07–0.75, P = 0.020). In multivariable analysis, combined positivity of both markers was significantly associated with longer OCSS in the discovery set (HR = 0.20, 95% CI = 0.06–0.49, P < 0.001) and in the validation set (HR = 0.33 95% CI = 0.07–0.1.06, P = 0.047). In a stratified analysis for stage IC/II EC, combined positivity identified a subset of patients with a significantly longer OCSS in the discovery cohort but only a non‐significant trend in the validation cohort. Conclusions Nuclear β‐catenin and CDX2 expression individually or in combination are validated prognostic markers for ovarian EC. However, their full potential to stratify low risk patients at adjuvant threshold awaits further multimarker study.

show abstract

“…Among cases of stage I endometroid carcinoma, Chao at el. also found that grade 3 tumors were an independent poor prognostic factor in terms of PFS 22 . However, it remains controversial whether grade correlates with unfavorable survival outcomes in mucinous carcinomas 23 .…”

Section: Second Malignancies Among Women With Early-stage Eoc Who Fssmentioning

confidence: 79%

“…It is di cult to distinguish whether the second malignancy was a metastatic endometrioid endometrial cancer from the ovary or a synchronous cancer. Zhao et al reported thatpatients with stage I ovarian endometrioid carcinoma had a 19.3% rate of synchronous early stage and well-to-moderate differentiated endometrial carcinoma 22 . Notably, in our study, uterine cancer also developed in patients with ovarian cancerof the other histologies.…”

Section: Second Malignancies Among Women With Early-stage Eoc Who Fssmentioning

confidence: 99%

Outcomes After Fertility-sparing Surgery of Early-stage Ovarian Cancer: a Nationwide Population-based Study

Lee

Chiang

Tai

et al. 2022

Preprint

View full text Add to dashboard Cite

Here we investigated the outcomes of early-stage epithelial ovarian cancer (EOC) following fertility-sparing surgery (FSS)or radical comprehensive staging surgery (RCS), as well as the suitability of FSS.Our analysis included 1297 early-stage EOC cases in the Taiwan Cancer Registry (TCR) database, which were newly-diagnosed between 2009–2017. Based on site-specific surgery codes, patients were divided into two groups:FSS (401 patients) and RCS (896 patients). Cancer-specific survival (CSS) was evaluated using the Kaplan–Meier method with log-rank testing and Cox models. Compared to the FSS group, patients in the RCS group were older (p < 0.001) and more commonly received adjuvant chemotherapy (p<0.001). Independent poor prognostic factors for CSS includedstage (p<0.001)and histologic grade (p< 0.001), but not histologic type (p= 0.13).CSS was similar between women who underwent FSS and those who underwent RCS (p=0.75).FSS group did not show significantly poorer CSS compared with RCS group in serous, mucinous, or endometrioid histologic type. Whereas, among clear cell carcinoma, FSS group had better CSS (HR: 0.28, 95% CI: 0.06–0.82, p=0.040) than RCS group. Endometrioid ovarian cancer patients had the highest frequency of developing second malignancies.FSS canbe a safe alternative procedure in selected young women with early-stage EOC who wish to preserve fertility regardless histologic type. Patients who receive FSS must undergo regular surveillance to detect disease recurrence and second malignancies.

show abstract

Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma

Cited by 9 publications

References 20 publications

A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer

A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer

Nuclear β‐catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome

Outcomes After Fertility-sparing Surgery of Early-stage Ovarian Cancer: a Nationwide Population-based Study

Contact Info

Product

Resources

About